Inbiomotion, a spin-off of IRB Barcelona and the Catalan Institution for Research and Advanced Studies (ICREA) and a CataloniaBio & HealthTech member, has closed a round of investment led by Alta Life Sciences. The total amount invested has not been disclosed publicly, although the round included existing investors like the Catalan Institute of Finance (ICF).

Inbiomotion is developing a test to diagnose breast cancer using a predictive biomarker (MAF test). Clinical trials have shown this biomarker can identify patients with early-stage breast cancer, who would benefit from bisphosphonates in adjuvant treatment to improve life expectancy. 

This capital increase will be used to complete regulatory development to begin commercialising the product in 2022.

More information

Photo: Roger Gomis, founder of Inbiomotion, at a Lessons Learned debate organised by CataloniaBio & HealthTech.

You may also be interested in:

• Entrepreneurialism to fight cancer, in the newspaper Ara
• Impress the evaluator to get an SME Instrument